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osting by E
cense.Abstract An easy and efﬁcient route for the synthesis of some tetrazolo[1,5-a]-, pyrazolo[1,5-a]-
and pyrimido[1,6-a] pyrimidine derivatives was described through the reaction of sodium salts of
formyl ketones with 5-aminotetrazole, 5-aminopyrazole derivatives and 6-aminothiouracil, respec-
tively. The antimicrobial screening of some derivatives of the prepared compounds has been
achieved, and it exhibited a moderate activity against the tested microorganisms.
ª 2009 King Saud University. Open access under CC BY-NC-ND license.1. Introduction
Purine compounds play an essential role in several biological
processes and have very important chemical and pharmacolog-
ical importance. It has been declared that tetrazolopyrimidines
are used in the treatment of obesity, diabetes, atherosclerosis,
hypertension, coronary heart disease, hypercholesterolemia,
hyperlipidemia, thyroid cancer, hypothyroidism, depression,ity.
lsevierglaucoma, cardiac arrhythmias, and congestive heart failure
(Takayama et al., 2006; Fujii et al., 2005; Takaya et al.,
1988; Utsunomiya et al., 1999; Aspnes, 2002; Uehata et al.,
2001). Pyrazolopyrimidine systems, as they are structurally re-
lated to purine, are considered typical examples of purine ana-
logues that are reported as inhibitors for the synthesis of DNA
and RNA in the cells of some kinds of cancers (Seela et al.,
2000) and viruses, (Tominage et al., 1990; Moukha-chaﬁq
et al., 2002) and many other biological activities for these com-
pounds are reported (Moore and Pharm, 2000; Sanna et al.,
2002; Erman and Insomnia, 2000; Quintela et al., 2001; Fore-
man and Garland, 1976; Dunbar et al., 1979; Gross, 2006).
Whereas pyrimidopyrimidines, analogues of folic acid (one
of the B vitamins that is a key factor in the synthesis of nucleic
acids RNA and DNA), have been screened for anti-tumor
activity (Delia et al., 1993) as they exhibit observable inhibi-
tion of the human Epidermal Growth Factor Receptors
(EGFRs) that occurs frequently in human cancers and is
associated with aggressive tumor behavior and poor patient
62 A.M. Husseinprognosis (Solca et al., 2004). Furthermore, pyrimidopyrimi-
dine systems are useful as bronchodilators and, vasodilators
(Taylor et al., 1960; Figueroa Villar et al., 1992), and as anti-
cancer (Coate, 1990), antiallergic (Kitamura and Onishi,
1984a,b), and antihypertensive (Raddatz and Bergmann,Table 1 Characterization data of compounds 6, 11 and 13.
Compd. No. M.P. (C)
Solvent
Color
Yield%
6a 182–183
EtOH
Pale brown
69.1
6b 119–121
EtOH
Orange
73.3
6c 103–105
EtOH
White
64
6d 110–112
EtOH
White
73
11a 188–190
EtOH
Pale yellow
96.0
11b 188–189
EtOH
Yellow
72.2
11c 199–200
EtOH
Orange
69.5
11d 180–181
EtOH
Pale yellow
60.7
13a 205–207
Dioxan
Reddish yellow
65.6
13b 255–256
Dioxan
Orange
62.9
13c 261–263
Dioxan
Pale yellow
66
13d 233–234
Dioxan
Orange
68.8
13e 242–244
Dioxan
Yellow
62.9
13f 270–271
Dioxan
Pale orange
70
13g 259-261
Dioxan
Orange
70.1
13h 171–173
Dioxan
Orange
69
Table 2 Characterization data of compounds 15–17.
Compd. No. M.P. (C)
Solvent
Color
Yield%
Mo
(M.
15a 276–277
EtOH
Pale brown
71.6
C10
(219
15b 230–232
EtOH
Yellow
75.2
C11
(233
15c 249–251
EtOH
Yellow
81
C13
(261
15d 230–231
EtOH
Yellow
70.3
C17
(317
16 266–268
EtOH
Pale yellow
61.1
C8H
(193
17 288–289
EtOH/DMF
Yellowish green
63
C13
(2551988a,b) agents. Here, an easy construction of some new and
interesting pyrimidopyrimidines, the ring systems that can be
found in marine-derived natural products such as crambesci-
din (Suider and Shi, 1993) and batzelladine (Patil et al.,
1995) alkaloids, has been achieved.Mol. formula
(M.Wt.)
Elemental analysis calc./found%
C H N
C7H7N5
(161)
52.17
52.22
4.35
4.19
43.47
43.66
C8H9N5
(175)
54.85
54.88
5.14
5.00
40.00
39.79
C10H13N5
(203)
59.11
58.89
6.40
6.65
34.48
34.45
C14H21N5
(259)
64.86
64.49
8.11
8.21
27.03
27.00
C20H17N5O
(343)
69.97
69.84
4.96
4.69
20.41
20.64
C21H19N5O
(357)
70.58
70.52
5.32
5.29
19.60
19.50
C20H16N5OCl
(377.5)
63.57
63.88
4.24
4.25
18.54
18.22
C21H19N5O2
(373)
67.56
67.29
5.09
5.30
18.76
18.56
C25H19N5O
(405)
74.07
74.21
4.69
4.66
17.28
17.54
C26H21N5O
(419)
74.46
74.33
5.01
5.11
16.70
16.59
C25H18N5OCl
(439.5)
68.26
68.00
4.10
4.21
15.92
16.01
C26H21N5O2
(435)
71.72
71.48
4.83
4.89
16.09
16.18
C25H18N5OBr
(484)
61.98
61.77
3.72
3.70
14.46
14.42
C26H20N5OCl
(453.5)
68.79
68.65
4.41
4.35
15.43
15.40
C25H17N5OCl2
(474)
63.30
63.00
3.58
3.11
14.76
14.54
C26H19N5O2
(433)
72.05
72.22
4.38
4.32
16.16
16.27
l. formula
Wt.)
Elemental analysis calc./found%
C H N S
H9N3OS
)
54.79
54.88
4.11
4.22
19.17
19.00
14.61
14.60
H11N3OS
)
56.65
56.66
4.72
4.66
18.02
18.22
13.73
13.71
H15N3OS
)
59.77
59.55
5.74
5.89
16.09
15.99
12.26
12.26
H23N3OS
)
64.35
64.34
7.25
7.45
13.24
13.33
10.0
910.11
7N3OS
)
49.74
49.58
3.63
3.61
21.76
21.65
16.58
16.65
H9N3OS
)
61.17
61.24
3.53
3.42
16.47
16.45
12.55
12.34
Synthesis of some new purine-related compounds: Regioselective one-pot synthesis 632. Experimental
All melting points were determined on an electrothermal appa-
ratus and are uncorrected. IR spectra were recorded (KBr
discs) on a BRUKER IFS-25 FT-IR spectrophotometer at
the region 400–4000 cm1. 1H NMR spectra were recorded
in CDCl3 and (CD3)2SO solutions on a Varian Gemini
300 MHz spectrometer and chemical shifts are expressed in d
units using TMS as an internal reference. Mass spectra were
recorded on a GC–MS QP 1000 EX Shimadzu. Elemental
analyses were carried out at the Microanalytical Center of
the Cairo University, Giza, Egypt. The antimicrobial screening
was carried out at the Faculty of Pharmacy, Bani-Suef Univer-
sity. Aminopyrazoles 9 were prepared according to the litera-
ture procedure (Elgemeie et al., 1997, 1998). PiperidineO
HCOOC2H5
OH
O
N N
NN
HOH
OH NH
N
NN
NN
CH3ONa
(7)
(8)
( )
n
(1)
( )
n
+
a,  n = 1
b,  n = 2
c,  n = 4
d,  n = 8
( )
n
( )
n
( )
n
- 2H2O
pip. acetate
AcOH
Chart 1acetate was prepared by the addition of 5 ml piperidine to a
mixture of 4 ml acetic acid and 10 ml water (Patil et al.,
1995; Johnson and Mathews, 1947).
2.1. Synthesis of tetrazolo[1,5-a]pyrimidine derivatives 6a–d,
pyrazolo[1,5-a]-pyrimidine derivatives 11a–d and 13a–h
2.1.1. General procedure
The respective mixtures of 5-aminotetrazole monohydrate 4, 5-
aminopyrazoles 9a–d, or 9a–h (0.01 mol) were reﬂuxed in a
solution of sodium salts 2, 10, or 12 (0.012 mol) and piperidine
acetate (1.5 ml) for 3–5 min. Acetic acid (1.5 ml) was added to
the reaction mixture while boiling, then the mixture was cooled
and the solid product was collected by ﬁltration and recrystal-
lized from a suitable solvent (Table 1).O
OH
O Na
O
OH
OHH
N
NH
N
N
NH
N
N N
N
N
N
NH
N
N
NH2
(6)
(4)
(5)
_
+
(2)
H2O
( )
n(3)
( )
n
( )
n
- 2H2O
a,  n = 1
b,  n = 2
c,  n = 4
d,  n = 8
/
64 A.M. Hussein2.2. Synthesis of pyrimido[1,6-a]pyrimidine derivatives 15a–d,
16 and 17
2.2.1. General procedure
A mixture of equivalent amounts of sodium salts 2, 10, or 12
(0.012 mol) and 6-aminothiouracil was reﬂuxed with a solution
of piperidine acetate (1.5 ml) for 15–20 min. The reaction mix-
ture was then diluted with 20 ml ethanol and reﬂuxed for an-
other 1 h. The reaction was quenched by the addition of
1.5 ml acetic acid, then the mixture was cooled and the solid
product was collected by ﬁltration and recrystallized from
the appropriate solvent (Table 2).
3. Results and discussion
Since the direct introduction of some speciﬁc substances for
the construction of tetrazolopyrimidines nucleus is not always
easy, new methods for the direct synthesis of these compounds
from readily available starting materials have been of great
interest. Some novel tetrazolopyrimidines have been synthe-
sized by the reaction of 5-aminotetrazole and the early-synthe-
sized sodium salts of formyl ketones 2 (Johnson and Mathews,
1947; Mariella, 1947; Litvinov et al., 1984; Elgemeie and Ali,
2002). Thus, treatment of 5-amino-1H-tetrazole hydrate 4 with
sodium (2-oxocycloalkylidine)methenoates 2 in the presence of
aqueous piperidine acetate and acetic acid as a one-step reac-
tion afforded in a good yield (69–73%) the solid reaction prod-
ucts. The reaction products were suggested to be cycloalkane
ring-fused tetrazolo[1,5-a]pyrimidines 6 and not the isomeric
tetrazolopyrimidines 8 as outlined in Chart 1.N
N
N
N
N
N
N
N
N
N
N
+.
m/z = 175 (32.8 %)
- CH2=CH2 (28)
m/z = 147 (7.10%)
- N2  (28)
- N2 (28)
m/z = 63 (11.8%)
+.
+.
SchemeThe reaction mode for the formation of the products is sug-
gested to proceed through the initial nucleophilic attack by the
exocyclic amino group at the formyl group of compound 3 that
formed in situ due to the reaction of the formyl salts 2 with
water, followed by cyclization through the elimination of
two water molecules leading to the formation of the reaction
products 6.
The suggestion of the formation of the alternative isomeric
planar products 8 is based on the probability of the initial at-
tack of the indocyclic NH of the tetrazole ring, which is ex-
pected to be more nucleophilic at the formyl group in 3
followed by cyclization and elimination of water. This sugges-
tion is principally excluded due to the more steric hindrance
around the endocyclic nitrogen atom than around the exocy-
clic one that can easily attack the unhindered and electroni-
cally favoured formyl group of compound 3 (Elgemeie and
Ali, 2002; Hussein et al., 2007).
The characterization of the reaction products was con-
ﬁrmed by using the available elemental analysis and spectral
data (IR, Ms, and 1H NMR). Thus, the IR spectrum of com-
pound 6b showed the absence of the bands related to NH or
NH2 of the start and revealed bands at m= 2948 cm
1 (par-
afﬁnic CH), 1655 cm1 (C‚N), and at 1619 cm1 (C‚C).
The 1H NMR spectrum revealed the presence of signals
at d= 1.96–2.11 ppm (m, 4H, 2CH2), 2.91–3.33 (m, 4H,
2CH2), and 8.70 (s, 1H, pyrimidine proton). Its mass spec-
trum showed a molecular ion peak at m/z= 175 (32.8%)
coincident with the molecular weight of the compound
(175.19) and revealed the base peak at 107 (100%) (Scheme
1) (Table 3).N
NN3
N
N
N
N
N
N
+.
m/z = 175
m/z = 119 (16.2%)
- CH2=CH2 (28)
m/z = 91 (11.6%)
+.
+.
1
Table 3 The spectral data of the newly synthesized compounds.
Compd.
No.
Spectra
6a IR m (cm1): 2920–2823 (CH paraﬃnic); 1665 (C‚N) and 1594 (C‚C)
1H NMR dH (ppm): 1.90–2.22 (m, 2H, CH2); 2.87–3.16 (m, 4H, 2CH2) and 8.72 (s, 1H, pyrimidine H)
Mass (m/z): 161 (M+, 10.0%); 151 (65.5%); 122 (73.0%); 95 (81.5%) and 67 (100.0%)
6b IR m (cm1): 2948 (paraﬃnic CH); 1655 (C‚N) and 1619 (C‚C)
1H NMR dH (ppm): 1.96–2.11 ppm (m, 4H, 2CH2); 2.91–3.33 (m, 4H, 2CH2) and 8.70 (s, 1H, pyrimidine H)
Mass (m/z): 175 (M+, 32.8%); 146 (10.4%); 107 (M+, 100%) and 79 (39.6%)
6c IR m (cm1): 2943–2845 (CH paraﬃnic); 1658 (C‚N) and 1589 (C‚C)
1H NMR dH (ppm): 1.36–2.00 (m, 4H, 2CH2); 2.67–2.95 (m, 4H, 2CH2); 3.48–3.53 (m, 4H, 2CH2) and 8.723 (s, 1H, pyrimidine H).
Mass (m/z): 204 (M++1, 31.6%); 203 (48.7%); 174 (13.50%); 146 (31.3%); 107 (48.0%) and 81 (48.7%)
6d IR m (cm1): 2920–2853 (CH paraﬃnic); 1659 (C‚N) and 1606 (C‚C)
Mass (m/z): 259 (M+, 7.3%); 233 (56.1%); 192 (18.3%); 176 (36.0%); 148 (48.1%) and 123 (100.0%)
11a IR m (cm1): 3304–3295 (NH); 1653 (enolic C‚O) and 1597 (C‚N)
1H NMR dH (ppm): 2.77 (s, 3H, CH3); 6.68–7.76 (m, 10H, Ar); 8.32 (s, 1H, pyrimidine C‚CH); 8.34 (s, 1H, pyrimidine N‚CH);
9.54 (s, 1H, NH) and 9.88 (s, 1H, NH)
Mass (m/z): 343 (M+, 38.7%); 251 (100.0%); 223 (3.6%); 132 (1.40%); 105 (2.0%); 78 (4.1%) and 64 (13.9%).
11b IR m (cm1): 3308–3290 (NH); 1659 (enolic C‚O) and 1600 (C‚N)
Mass (m/z): 358 (M++1, 14.2%); 251 (46.8%); 121 (12.0%); 111 (4.2%) and 64 (9.0%)
11c IR m (cm1): 3304–3288 (NH); 1661 (enolic C‚O) and 1596 (C‚N)
1H NMR dH (ppm): 2.71 (s, 3H, CH3); 6.66–7.98 (m, 9H, Ar); 8.41 (s, 1H, pyrimidine C‚CH); 8.43 (s, 1H, pyrimidine N‚CH);
9.55–958 (br s, 1H, NH) and 9.85 (s, 1H, NH)
Mass (m/z): 379 (M++2, 12.2%); 286 (63.5%); 210 (12.3%); 198 (3.4%); 106 (4.2%) and 76 (11.3%)
11d IR m (cm1): 3300–3286 (NH); 1664 (enolic C‚O) and 1601 (C‚N)
13a IR m (cm1): 3311 (NH); 1648 (enolic C‚O) and 1597 (C‚N)
1H NMR dH (ppm): 6.98–8.22 (m, 15H, Ar); 8.53 (s, 1H, pyrimidine C‚CH); 8.55 (d, 1H, pyrimidine N‚CH); 9.65 (s, 1H, NH)
and 10.14 (s, 1H, NH)
Mass (m/z): 405 (M+, 59.7%), 313 (100.0%); 285 (4.0%); 193 (1.70%); 90 (1.60%) and 64 (30.0%)
13b IR m (cm1): 3314 (NH); 1649 (C‚O) and 1612 (C‚N)
1H NMR dH (ppm): 2.11 (s, 3H, CH3); 6.99–8.00 (m, 14H, Ar); 8.46 (s, 1H, pyrimidine C‚CH); 8.56 (d, 1H, pyrimidine N‚CH)
and 9.71–9.99 (broad, 2H, 2NH)
13c IR m (cm1): 3316, 3259 (NH); 1652 (C‚O) and 1603 (C‚N)
13d IR m (cm1): 3302, 3260 (NH); 1651 (C‚O) and 1600 (C‚N)
1H NMR dH (ppm): 2.89 (s, 3H, OCH3); 7.00–8.12 (m, 14H, Ar); 8.25 (s, 1H, pyrimidine C‚CH); 8.33 (d, 1H, pyrimidine
N‚CH) 9.65 (br s, 1H, NH) and 9.69 (s, 1H, NH)
13e IR m (cm1): 3304–3265 (NH); 1655 (C‚O) and 1597 (C‚N)
Mass (m/z): 485 (M++1, 19.1%), 313 (100.0%); 103 (11.5%) and 77 (21.4%)
13f IR m (cm1): 3308–3255 (NH); 1662 (C‚O) and 1611 (C‚N)
13g IR m (cm1): 3335–3260 (NH); 1655 (C‚O) and 1601 (C‚N)
Mass (m/z): 476 (M++2, 63.3%), 405 (100.0%); 364 (11.2%); 298 (2.3%); 182 (11.6%) and 106.4 (31.6%)
13h IR m (cm1): 3377, 3273 (NH); 1665 (C‚O); 1650 (C‚O) and 1659 (C‚N)
1H NMR dH (ppm): 6.98–8.25 (m, 15H, Ar); 8.21–8.31 (br s, 2H, pyrimidine H’s) 9.74 (s, 1H, NH) and 10.01 (s, 1H, NH)
15a IR m (cm1): 3325 (NH); 2967 (–CH); 1671 (C‚O); 1609 (C‚N) and 1243 (C‚S)
Mass (m/z): 221 (M++2, 6.6%); 219 (M+, 100.0%); 161 (34.8%); 131 (14.5%); 104 (19.6%) and 77 (18.8%)
15b IR m (cm1): 3390 (NH); 2936 (–CH); 1658 (C‚O); 1624 (C‚N) and 1255 (C‚S)
Mass (m/z): 235 (M++2, 6.7%); 233 (M+, 100.0%); 175 (18.1%); 143 (31.7%); 119 (15.8%) and 68 (25.2%)
15c IR m (cm1): 3400 (NH); 2927 (–CH); 1680 (C‚O); 1613 (C‚N) and 1245 (C‚S)
1H NMR dH (ppm): 1.29–1.67 (m, 4H, 2CH2); 2.42–2.92 (m, 4H, 2CH2); 3.22–3.41 (m, 4H, 2CH2), 7.99 (s, 1H, pyrimidine N‚C–
H); 8.01 (s, 1H, pyrimidine C‚CH) and 12.91 (br s, 1H, SH)
Mass (m/z): 261 (M+, 100.0%); 323 (15.0%); 173 (7.4%); 103 (3.6%) and 77 (11.8%)
15d IR m (cm1): 3352 (NH); 2923 (–CH); 1679 (C‚O); 1621 (C‚N) and 1246 (C‚S)
Mass (m/z): 319 (M++2, 19.8%); 317 (M+, 94.0%); 246 (25.5%); 207 (100.0%); 147 (21.2%) and 91 (19.0%)
16 IR m (cm1): 3368 (NH); 2970 (–CH); 1627 (C‚O); 1591 (C‚N) and 1243 (C‚S)
Mass C‚ (m/z): 193 (M+, 37.4%); 189 (100.0%); 161 (25.2%); 91 (20.3%) and 75 (42.3%)
17 IR m (cm1): 3325 (NH); 2970 (–CH); 1630 (C‚O); 1592 (C‚N) and 1243 (C‚S)
Mass (m/z): 255 (2.9%); 151 (65.5); 95 (81.5%); 80 (17.3%) and 67 (100.0)
1H NMR dH (ppm): 6.89–7.89 (m, 5H, Ar); 8.10 (s, 1H, pyrimidine N‚C–H); 8.21 (s, 1H, pyrimidine C‚CH) and 12.68 (s, 1H,
SH)
Synthesis of some new purine-related compounds: Regioselective one-pot synthesis 65The behavior of aminopyrazoles towards the sodium for-
myl salts of aliphatic and aromatic acyclic ketones was also
investigated [we have previously reported their reaction with
the formyl salts of cyclic ketones (Hussein et al., 2007)] in asimilar manner. Thus, condensation of 5-aminopyrazole
derivatives 9a–d with sodium formylacetone 10 afforded the
2-anilino-7-methyl-N-arylpyrazolo[1,5-a]pyrimidine-3-carbox-
amides 11a–d. On the other hand, 9a–h reacted with sodium
66 A.M. Husseinformyl acetophenone 12 to give the 2-anilino-7-phenyl-N-aryl-
pyrazolo[1,5-a]pyrimidine-3-carboxamides 13a–h as shown in
Chart 2.
The structures of compounds 11 and 13 were conﬁrmed on
the basis of their elemental analysis and spectral data. Thus,
11a showed a correct elemental analysis that was compatible
with the molecular formula C20H17N5O. The IR spectrum
showed the absence of the peaks related to NH2 of the starting
pyrazole and revealed bands at m= 3304 cm1 (NH) and at
1653 cm1 (enolic C‚O). Its 1H NMR revealed a singlet
at d= 2.77 ppm related to the CH3 group; 6.68–7.76 ppm
(m, 10H, aromatic protons); 8.32 (s, 1H, pyrimidine C‚CH);
8.34 (s, 1H, pyrimidine N‚CH); 9.54 (s, 1H, NH) and 9.88 (s,NH N
NO
S
N N
NO
SH
N N
NOH
S)( n )( n )( n1H, NH). The mass spectrum of this compound revealed a
molecular ion peak at m/z= 343 (38.7%) coincident with
the molecular formula C20H17N5O (343.39) and showed the
base peak at m/z= 251.
The construction of pyrimido[1,6-a]pyrimidine ring systems
is almost a multistep synthesis (Hirota et al.,1984,1990; Srvast-
ava et al., 1999). However, our synthetic strategy commencesN
R
R
O
O NaPh
N
N
NR
R
Ph
1
(9)
1_ +
(13)
(12)
1
R R
NHPh
NHPh
NHPh
CONHPh
CONHPhMe-p
CONHPhCl-p
CONHPhOMe-p
CONHPhBr-p
CONHPhMe-p
CONHPhCl-p
CONHPh
NHPh
NHPh
NHPhCl-p
NHPhCl-p
NHCOPh
(13)
a
b
c
d
e
f
g
h
Chart 2from the easily available compound, 6-aminothiouracil and
the sodium salts of formyl ketones, which led to the direct con-
struction of the novel pyrimido[1,6-a]pyrimidine nucleus.
Thus, fusion of 6-aminothiouracil with the formyl salts 2 in
piperidine acetate and acetic acid afforded in considerable
yields the cyclocondensed pyrimido[1,6-a]-pyrimidines 15a–d
as outlined in Chart 3.
The identity of compounds 15 was proven on the basis of
their elemental analysis and spectral data. As the nucleus of
pyrimido[1,6-a]pyrimidine may exist in more than one resonat-
ing form, these forms must be taken into consideration while
discussing its spectral data. This ring system may be found
in three resonating forms:Thus, the IR of 15c revealed bands at m= 3400 cm1 (NH);
2927 (parafﬁnic CH); 1680 (C‚O); 1613 (C‚N) and 1245
(C‚S). The 1H NMR spectrum showed signals at d= 1.29–
1.67 ppm (m, 4H, 2CH2); 2.42–2.92 (m, 4H, 2CH2); 3.22–
3.41 (m, 4H, 2CH2); 7.99 (s, 1H, pyrimidine N‚C–H); 8.01
(s, 1H, pyrimidine C‚CH) and 12.91 (br s, 1H, SH). The mass
spectrum of this compound showed a molecular ion peak atNH
NH2 CH3
O
O Na
N
CH3
N
NR
R
1
_
+
(10)
(11)
1
R R
a
b
c
NHPh
NHPh
NHPh
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CONHPhCl-p
(11)
d NHPh          CONHPhOMe-p    
Table 4 The MIC’s of the tested compounds.
Compd. No. S. aureus B. subtilis E. coli Ps. aeruginosa C. albicans
6a P1600 P800 P800 P800 P800
11b P1600 P800 P800 P800 400
11c P1600 P800 P800 P800 P800
13b P1600 P800 P800 P800 P800
14a P1600 P800 P800 P800 P800
15a P1600 P800 P800 P800 P800
15b P1600 P800 P800 P800 P800
15c P1600 P800 P800 P800 P800
15d P1600 P800 P800 P800 P800
17 P1600 P800 P800 P800 P800
DMSO >1600 >800 >800 >800 >800
Ciproﬂoxacin 6100 625 625 400 P800
Triﬂucan P800 P800 P800 P800 625
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Synthesis of some new purine-related compounds: Regioselective one-pot synthesis 67m/z= 261 (100%) coincident with the molecular weight of the
compound (261.35).
For establishment of the phenomenon, a successful trial has
been carried out by the reaction of 6-aminothioiuracil with the
sodium salts of acyclic ketones 10 and 12 under the same reac-
tion conditions to afford 4-methyl-6-thioxo-6,7-dihydro-8H-
pyrimido[1,6-a]pyrimidin-8-one 16 and 4-phenyl-6-thioxo-6,7-
dihydro-8H-pyrimido[1,6-a]pyrimidin-8-one 17, respectively.
The structure compound 16 was established by its correct ele-
mental analysis and the IR spectrum which revealed bands at
m= 3325 cm1 (NH); 1627 (C‚O) and 1243 (C‚S). The mass
spectrum showed a molecular ion peak at m/z= 193 (37.4%)
coincident with its molecular weight (193.23) and the base
peak appeared at m/z= 189 (100%). The IR of compound
17 showed bands at m= 3323 cm1 (NH); 1630 (C‚O) and
1244 (C‚S). The mass spectrum showed the molecular ion
peak at m/z= 255 (1.7%) coincident with its molecular weight
(255.30).
4. Biological activities
The selected compounds were screened for their antimicrobial
activity using ﬁve selected standard isolates which have been
chosen as representative examples of different types of micro-
organisms as follows: Gram’s positive both non sporulated
bacteria as Staphylococus aureus and sporulated as Bacillus
subtilis, Gram’s negative as Escherichia coli and Pseudomonas
aeruginosa and a fungus as Candida albicans.
5. Method: agar dilution technique (El-helby, 2001)
The appropriate volumes of membrane-ﬁltered stock solution
of 0.05 g/5 ml of each compound were prepared by the twofolddilution method to obtain the following concentrations: 400,
200, 100, 50 and 25 (lg/ml). The volumes were added to the
molten LB agar (about 50 C). After mixing, the media were
allowed to harden and dry by placing in an incubator at
37 C for 10 min.
Plates containing serial dilutions of each compound were
inoculated with a sterile multi-inoculator onto the surface of
the agar medium so that the ﬁnal inoculum of each isolate
on the agar surface was in the order of 104–105 CFU/spot.
Ciproﬂoxacin and triﬂucan were used as positive controls
and the solvent, dimethylsulfoxide (DMSO) was used as a neg-
ative control. Minimum inhibitory concentrations (MIC’s)
were read after 18 h incubation at 37 C for bacteria and
25 C for fungus. The MIC is reported as the lowest concentra-
tion of the compound that prevents the growth of visible col-
68 A.M. Husseinonies. From the obtained results, there is variability in the sus-
ceptibilities of the different organisms to the different tested
compounds. S. aureus was the most resistant organism. Some
compounds showed antibacterial activity, while others showed
antifungal activity. The obtained MIC’s of 10 representative
examples are presented in Table 4.
The study of some other important biological activities
in vivo and in vitro of some newly synthesized compounds is
now under investigation in another separate work.
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